Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Tue, Mar 18, 2025
[Archive]
Volume 1, Issue 3 (1-2010)
Caspian J Intern Med 2010, 1(3): 111-114 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mobini M. Severe muscle weakness during treatment with pegylated interferon alfa for chronic hepatitis C virus infection A rare complication. Caspian J Intern Med 2010; 1 (3) :111-114
URL: http://caspjim.com/article-1-85-en.html
URL: http://caspjim.com/article-1-85-en.html
Abstract: (8738 Views)
Background: Interferons (IFNs) are common therapeutics for several diseases such as viral hepatitis, multiple sclerosis and malignancy. A variety of autoimmune related side effects have been observed during IFN therapy. Rare cases of myopathy, polymyositis or dermatomyositis have been reported during therapy with high doses of IFNα.
Case Presentation: In this report, we describe a case with severe muscle weakness but near normal muscles' enzymes during treatment of chronic hepatic C infection with pegylated IFN α 2a in a patient with major beta thalassemia
Conclusion: This report suggests that severe weakness with normal musclesα enzymes may occur during IFN therapy.
Case Presentation: In this report, we describe a case with severe muscle weakness but near normal muscles' enzymes during treatment of chronic hepatic C infection with pegylated IFN α 2a in a patient with major beta thalassemia
Conclusion: This report suggests that severe weakness with normal musclesα enzymes may occur during IFN therapy.
Type of Study: Original Article |
Subject:
Infectious Diseases
Received: 2014/01/14 | Accepted: 2014/01/14 | Published: 2014/01/14
Received: 2014/01/14 | Accepted: 2014/01/14 | Published: 2014/01/14
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
